GW Pharmaceuticals Plc (GWP)-医療機器分野:企業M&A・提携分析

◆英語タイトル:GW Pharmaceuticals Plc (GWP) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA8011095
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月21日
◆ページ数:32
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
GW Pharmaceuticals plc (GW Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes innovative therapeutics from its proprietary cannabinoid product platform. The company’s commercialized product, Sativex is a plant-derived cannabinoid prescription drug, for the treatment of spasticity due to multiple sclerosis. It sells and distributes the product through strategic collaborations with other pharmaceutical companies. GW Pharmaceuticals is also developing other products that are focused at treating Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis, infantile spasms, epilepsy, glioma, schizophrenia, autism among others. The company along with its subsidiaries operates in the US, England and Wales. GW Pharmaceuticals is headquartered in Cambridgeshire, the UK.

GW Pharmaceuticals Plc (GWP) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
GW Pharmaceuticals Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Medical Equipment, Deals By Market, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
GW Pharmaceuticals Plc, Medical Equipment, Deal Details 10
Private Equity 10
Mentor Capital Invests USD1 Million in GW Pharma 10
Equity Offering 11
GW Pharma Raises USD317.4 Million in Public Offering of Shares 11
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 13
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 15
Acquisition 17
GW Pharma May Sell Itself 17
GW Pharmaceuticals Plc – Key Competitors 18
GW Pharmaceuticals Plc – Key Employees 19
GW Pharmaceuticals Plc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Aug 07, 2017: GW Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results 21
May 09, 2017: GW Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Operational Progress 23
Feb 07, 2017: GW Pharmaceuticals Reports First Quarter 2017 Financial Results and Operational Progress 25
Dec 05, 2016: GW Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress 26
Aug 09, 2016: GW Pharmaceuticals Reports Third Quarter 2016 Financial Results and Operational Progress 27
May 05, 2016: GW Pharmaceuticals Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress 28
Feb 10, 2016: GW Pharmaceuticals Reports First Quarter 2016 Financial Results and Operational Progress 29
Corporate Communications 30
May 15, 2017: GW Pharmaceuticals Announces Research & Development Management Appointments 30
Mar 07, 2017: GW Pharmaceuticals Announces the Appointment of Scott Giacobello as Chief Financial Officer and Adam George as Managing Director – UK 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
GW Pharmaceuticals Plc, Medical Equipment, Key Facts, 2016 2
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 2
GW Pharmaceuticals Plc, Medical Equipment, Deals By Year, 2011 to YTD 2017 5
GW Pharmaceuticals Plc, Medical Equipment Deals By Type, 2011 to YTD 2017 6
GW Pharmaceuticals Plc, Medical Equipment, Deals By Region, 2011 to YTD 2017 7
GW Pharmaceuticals Plc, Deals By Market, 2011 to YTD 2017 8
GW Pharmaceuticals Plc, Medical Equipment, Deals Summary, 2011 to YTD 2017 9
Mentor Capital Invests USD1 Million in GW Pharma 10
GW Pharma Raises USD317.4 Million in Public Offering of Shares 11
GW Pharma Raises USD126 Million in Public Offering of American Depositary Shares 13
GW Pharma Completes Public Offering Of American Depositary Shares For US$101 Million 15
GW Pharma May Sell Itself 17
GW Pharmaceuticals Plc, Key Competitors 18
GW Pharmaceuticals Plc, Key Employees 19
GW Pharmaceuticals Plc, Other Locations 20
GW Pharmaceuticals Plc, Subsidiaries 20

★海外企業調査レポート[GW Pharmaceuticals Plc (GWP)-医療機器分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Severoceske doly as:企業の戦略・SWOT・財務情報
    Severoceske doly as - Strategy, SWOT and Corporate Finance Report Summary Severoceske doly as - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Circassia Pharmaceuticals Plc (CIR)-医療機器分野:企業M&A・提携分析
    Summary Circassia Pharmaceuticals plc (Circassia) develops treatments for allergy and respiratory diseases such as asthma. The company’s product line includes NIOX, which is used to improve asthma management by assisting in diagnosis. In addition, the company's pipeline includes a number of inhaled …
  • Gannett Co., Inc.:戦略・SWOT・企業財務分析
    Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report Summary Gannett Co., Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alviva Holdings Ltd (AVV):企業の財務・戦略的SWOT分析
    Alviva Holdings Ltd (AVV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tung Lok Restaurants (2000) Ltd.:企業の戦略・SWOT・財務情報
    Tung Lok Restaurants (2000) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tung Lok Restaurants (2000) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Air Mauritius Ltd.:企業の戦略・SWOT・財務情報
    Air Mauritius Ltd. - Strategy, SWOT and Corporate Finance Report Summary Air Mauritius Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Pepticom Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pepticom Ltd (Pepticom) is a drug discovery and development company focused on novel peptide drug candidates. The company's artificial intelligence platform for peptide design models based on the target's solved crystal structure of the target protein. Its products includes copaxone, used fo …
  • Potlatch Corporation:戦略・SWOT・企業財務分析
    Potlatch Corporation - Strategy, SWOT and Corporate Finance Report Summary Potlatch Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Resilux NV:企業の戦略・SWOT・財務情報
    Resilux NV - Strategy, SWOT and Corporate Finance Report Summary Resilux NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Instituto Costarricense de Electricidad:企業の戦略的SWOT分析
    Instituto Costarricense de Electricidad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Swiss AviationSoftware Ltd.:企業の戦略的SWOT分析
    Swiss AviationSoftware Ltd. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Austin Industries, Inc.:企業の戦略・SWOT・財務情報
    Austin Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Austin Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Promore Pharma AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Promore Pharma AB (Promore), formerly Pergamum AB is a biopharmaceutical company that develops peptide-based product candidates for local and topical treatment of infections and wounds. The company’s pipeline products include LL-37 and PXL01 therapeutic peptides. Its PXL01 is used for the pr …
  • Cryo-Cell International Inc (CCEL):企業の財務・戦略的SWOT分析
    Summary Cryo-Cell International Inc (Cryo-Cell) operates as a cord blood bank service provider. The company offers biotechnology services, collection and preservation of umbilical cord blood stem cells for family use. It provides services such as cord blood banking, cord tissue banking, cord blood a …
  • Cell Signaling Technology Inc-医療機器分野:企業M&A・提携分析
    Summary Cell Signaling Technology Inc (CST) is a biotechnology company that develops and manufactures antibody products for medical research and clinical diagnostic market. The company products include primary antibodies, antibody samplers, secondary antibodies, antibody conjugates, ELISA Kits, anti …
  • AB Orlen Lietuva:企業の戦略的SWOT分析
    AB Orlen Lietuva - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Takeda Pharmaceuticals USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Takeda Pharmaceuticals USA Inc (TPUSA), formerly Takeda Pharmaceuticals North America Inc, a subsidiary of Takeda Pharmaceutical Company Ltd, is a developer, manufacturer and distributor of pharmaceutical drugs. The company’s products include pioglitazone and glimepiride, lubiprostone, piogl …
  • Booz Allen Hamilton Holding Corporation (BAH):企業の財務・戦略的SWOT分析
    Booz Allen Hamilton Holding Corporation (BAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • NOW Inc (DNOW):企業の財務・戦略的SWOT分析
    NOW Inc (DNOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆